Refine my results

Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients

Cattin, Sarah ; Fellay, Benoît ; Pradervand, Sylvain ; Trojan, Andreas ; Ruhstaller, Thomas ; Rüegg, Curzio ; Fürstenberger, Gregor

In: Oncotarget, 2016, vol. 7, no. 10, p. 11137–11150

Whether bevacizumab exerts its anti-tumor properties through systemic effects beyond local inhibition of angiogenesis and how these effects can be monitored in patients, remain largely elusive. To address these questions, we investigated bone marrow-derived cells and cytokines in the peripheral blood of metastatic breast cancer patients undergoing therapy with...